This study is looking at the drug lenacapavir (LEN) and a pill combination called emtricitabine/tenofovir disoproxil fumarate (F/TDF) to see if they can prevent HIV in cisgender women in the US. HIV is a virus that attacks the immune system. The study checks how well these drugs travel through the body (this is called pharmacokinetics) and if they are safe for women to use as pre-exposure prophylaxis (PrEP), which means taking medicine to prevent getting HIV before being exposed to it. It also looks at how acceptable women find getting LEN as an injection and taking F/TDF as a pill.

• The study involves women who have had condomless sex with a man in the past year.
• Participants should not have previous positive HIV test results or current hepatitis infections.
• It is important to not have used certain HIV prevention drugs in the past.

Participants will have several health checks, and the study will take some time, but it aims to find better ways to keep women safe from HIV.